For HER2+ breast cancer patients in neoadjuvant setting, the standard regimen to date was chemotherapy and trastuzumab (AC-TH, AC-PH, or TCbH), in which the pCR rates of 50% or more can be achieved (15, 19–21). Here, ERBB2 is linked to breast cancer.